Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China To Invest $1 Billion To Ramp Up New Drug Innovation

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - China will invest RMB 6.6 billion ($960 million) to launch a massive new drug development and manufacturing program from 2008 to 2010. Roughly 3,290 projects focused on preclinical studies and identifying new candidates are awaiting approval to initiate in 2009

You may also be interested in...



BIO Reaches Out To China, Encourages Harmonization

WASHINGTON - Chinese officials are in the process of building the country's biotech regulatory framework, and foreign and domestic companies see opportunities to help shape the country's path toward becoming a major biotech market

BIO Reaches Out To China, Encourages Harmonization

WASHINGTON - Chinese officials are in the process of building the country's biotech regulatory framework, and foreign and domestic companies see opportunities to help shape the country's path toward becoming a major biotech market

China’s Strongest Pharmas Likely To Thrive Through Innovation And Acquisition Despite Global Crisis

Analysts predict the country’s top 100 pharmas will collectively post a rise in operating profit of more than 20 percent in 2009.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067222

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel